BioSante licensing deal with Corixa
BioSante Pharmaceuticals says it has licensed its Bio-Vant vaccineadjuvant on a non-exclusive basis to Corixa Corp for use in a variety of cancer, infectious and autoimmune disease vaccines developed by the latter.
Under the terms of the deal, financial terms of which were not disclosed, Corixa will pay BioSante milestone and royalty payments if and when vaccines are approved using Bio-Vant. If the former firm then sub-licenses said vaccines, BioSante will share in any further payments received by Corixa.
Stephen Simes, BioSante's chief executive, said that the deal "helps validate our preclinical and clinical work with Bio-Vant and gives credence to the value of our partner-funded feasibility studies." He added that "several other unannounced partner-funded feasibility studies also are underway with both biotech and pharmaceutical companies."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze